Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study

(2020) Eric Nadler et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Update on emerging biomarkers in lung cancer

(2019) Eric H. Bernicker et al.   Journal of Thoracic Disease

Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer

(2019) G M Blumenthal et al.   ANNALS OF ONCOLOGY

44PTemporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative

(2019) M Snee et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer

(2019) M. Reck et al.   Journal of Thoracic Oncology

Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study

(2018) Marisa A. Bittoni et al.   Clinical Lung Cancer

Clinical characteristics and overall survival of patients diagnosed with non-small cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical practice: a retrospective analysis of a UK hospital database

(2018) M. Snee et al.   LUNG CANCER

62PFirst-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK

(2018) M Wang et al.   ANNALS OF ONCOLOGY

Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010

(2017) Filip Kaniski et al.   LUNG CANCER

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

(2017) Jessica Davies et al.   PLoS One

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview

(2008) Hatem A. Azim et al.   LUNG CANCER